Article
Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC.
BMC cancer - 4 Sept 2017
Brugnoli Federica, Grassilli Silvia, Lanuti Paola, Marchisio Marco, Al-Qassab Yasamin, Vezzali Federica, Capitani Silvano, Bertagnolo Valeria
Abstract excerpt
BACKGROUND: The malignant potential of triple negative breast cancer (TNBC) is also dependent on a sub-population of cells with a stem-like phenotype. Among the cancer stem cell markers, CD133 and EpCAM strongly correlate with breast tumor aggressiveness, suggesting that simultaneous targeting of the two surface antigens may be beneficial in treatment of TNBC. Since in TNBC-derived cells we demonstrated that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.